ManaT Bio, a KRAS biotech from Bert Vogelstein and Catalio, targets $153M with Third Rock partner as CEO

A new im­munother­a­py biotech from famed Johns Hop­kins on­col­o­gy re­searchers Bert Vo­gel­stein and Drew Par­doll is in the works, with a siz­able $153 mil­lion fi­nanc­ing round un­der­way.

Vo­gel­stein, who has found­ed can­cer de­tec­tion com­pa­nies like Thrive and Haystack On­col­o­gy, has been work­ing on a “mul­ti-year col­lab­o­ra­tion” with Par­doll to find mu­ta­tion-as­so­ci­at­ed neoanti­gens (hence MAN­As) that show up on the cell sur­face, ac­cord­ing to the com­pa­ny’s in­cu­ba­tor, Catalio Cap­i­tal Man­age­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.